摘要
青光眼是全球第二大致盲疾病,眼压增高是其主要危险因素,前列腺素类药物是新型的抗青光眼药物,广泛应用于临床,但其药物反应个体差异大,对其原因尚不明确,遗传变异可能是造成个体间反应差异的主要原因之一。本文对其可能的原因进行总结,希望能对临床个体化治疗和研究提供帮助。
Glaucoma is the world＇s and increased intraocular pressure is analogues are a new category drug as second largest cause of blindness, the main risk factor. Prostaglandin antiglaucoma agents, widely used in clinical, but there are large individual differences in drug response. The reason is still unclear. Genetic variation may be one of the main reasons for differences between individuals. This review will summarize the possi- ble reasons, hoping to provide help for clinical individual therapy and re- search.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第5期470-472,共3页
The Chinese Journal of Clinical Pharmacology
基金
国家十二五"重大新药创新"科技重大专项基金资助项目(2011ZX09302-007-05)
关键词
青光眼
药物基因组学
个体化治疗
FP受体
基因多态性
glaucoma
pharmacogenomics
individualized therapy
F -prostanoid receptor
gene polymorphism
